The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.

ABSTRACT:

Background

Bicalutamide is a nonsteroidal antiandrogen widely used as a first-line clinical treatment for advanced prostate cancer (PCa). Although patients initially show effective responses to bicalutamide treatment, resistance to bicalutamide frequently occurs and leads to the development of castration-resistant PCa (CRPC). This research investigated the roles of the oestrogen receptor α (ERα)-nuclear factor E2-related factor 2 (NRF2) signalling pathway in bicalutamide resistance in PCa cells.

Methods

We performed bioinformatic analysis and immunohistochemical staining on normal and cancerous prostate tissue to evaluate ERα and NRF2 expression and their correlation. Gene expression and localization in PCa cell lines were further investigated using real-time reverse transcr

SUBMITTER: Tian L 

PROVIDER: S-EPMC9661764 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature